Background: Platelet-derived microparticles (PMPs) are generally considered a marker of platelet activation in cardiovascular disease. We studied the extent to which PMP subpopulations parallel platelet activation in vitro and in vivo. Methods: Using flow cytometry, we analyzed PMP subpopulations from resting and activated platelets in vitro (n ‫؍‬ 6) as well as from plasma samples of patients with stable angina, peripheral arterial disease, or myocardial infarction [non-ST-elevation (NSTEMI) and ST-elevation (STEMI)] and from older, age-and sexmatched and young healthy individuals [n ‫؍‬ 10 for all groups except NSTEMI (n ‫؍‬ 11)]. Coagulation markers prothrombin fragment F 1 ؉ 2 and thrombin-antithrombin complexes were determined by ELISA. The PMPassociated fraction of soluble (s)P-selectin was estimated by ELISA. Results: In vitro, stimulation of platelets with thrombin receptor-activating peptide (15 mol/L) or the calcium ionophore A23187 (2.5 mol/L) increased fractions of both platelets and PMPs exposing P-selectin or CD63 (P <0.001 for all). Whereas the number of PMPs released by A23187-stimulated platelets increased significantly (P <0.001), the number of PMPs released from thrombin receptor-activating peptide-stimulated platelets remained constant (P >0.05). Ex vivo, numbers of circu-
is labor-intensive, and is complicated by fixation procedures, secretion products are either not very specific for platelets [e.g., soluble P-selectin (sP-selectin)] 4 or are sensitive to sampling and handling artifacts (e.g., thromboglobulin).
Indirect methods are functional platelet assays, which evaluate the ex vivo platelet function thought to be dependent on platelet activation status in vivo. In this way, both reversible (e.g., aggregation and adhesion) and irreversible platelet activation (i.e., the secretion response) can be studied. Although rapid platelet function assays have been developed, correlations with direct assays are poor, suggesting that such functional assays do not necessarily reflect the actual in vivo activation status (3 ) .
In vitro, the release of microparticles (MPs) from platelets [platelet-derived MPs (PMPs)] has been associated with the secretion response (4 ) . Therefore, the numbers of circulating PMPs reflect the platelet activation status in vivo, for example, in patients with peripheral arterial disease (5 ) , unstable angina (6 ) , myocardial infarction (MI) (7 ) , cerebrovascular accident (8, 9 ) , and diabetes (9 ) . Because analysis of PMPs does not require fixation and can be applied to stored plasma samples, batchwise analysis of the in vivo platelet activation status is feasible. However, although several studies have confirmed concomitant changes in exposure of platelet Pselectin and circulating numbers of PMPs in vivo (10, 11 ) , others found discrepancies between both (6, 7, (12) (13) (14) , which may call into question the relevance of PMP numbers as a marker of platelet activation.
We hypothesized that measuring PMP-associated Pselectin or CD63 is a feasible and reliable method for assessing platelet activation. Because of the intricacy of adequately assessing the in vivo platelet activation status, as discussed before, we first evaluated the exposure of P-selectin and CD63 on both platelets and PMPs under controlled in vitro conditions. To substantiate the relevance of our in vitro findings, we also determined the exposure of P-selectin and CD63 on circulating PMP in groups of individuals with various degrees of atherosclerotic disease. Finally, we measured the coagulation activation markers prothrombin fragment F 1 ϩ 2 and thrombin-antithrombin complexes (TATs), which are associated with platelet activation and PMP release (15 ) . 1 ) and allophycocyanin-labeled annexin V from Caltag; IgG2 b -PE (MCG2b) from Immuno Quality Products; and anti-CD63-PE (CLB-gran12, IgG 1 ) and anti-P-selectin-PE (CLB-Thromb/6, IgG 1 ) from Coulter/Immunotech. We had previously demonstrated that the anti-P-selectin antibody used does not cross-react with (endothelial) E-selectin (16 ) . Plasma concentrations of sP-selectin, F 1 ϩ 2 , and TAT were determined by ELISA as described by the manufacturer (Parameter human P-Selectin Immunoassay by R&D Systems and Enzygnost F 1 ϩ 2 micro and TAT by Dade-Behring Diagnostics GmbH, respectively).
Materials and Methods reagents and assays
in vitro platelet activation and flow cytometric analysis
We obtained venous blood from 6 healthy individuals who had not taken any medication during the previous 10 days and had given their informed consent. The blood was collected into 1/10th volume of 10.9 mmol/L trisodium citrate and was centrifuged at 180g for 15 min at 20°C to obtain platelet-rich plasma (PRP). PRP (3.5-4.5 mL) was acidified with 1/6th volume of acid-citratedextrose (71 mmol/L citric acid, 85 mmol/L trisodium citrate, and 110 mmol/L d-glucose, pH ϳ4.4). The acidified PRP from each healthy individual was divided into 2 aliquots. We added dibutyryl cAMP (final concentration, 2 mmol/L) to one of the aliquots; to the other we added nothing. The PRP was incubated for 20 min at 37°C. Platelets were then pelleted by centrifugation at 700g for 20 min at 20°C, then washed once with a buffer containing 137 mmol/L NaCl, 2.6 mmol/L KCl, 1.0 mmol/L MgCl 2 , 11.9 mmol/L NaHCO 3 , 5.6 mmol/L d-glucose, 1 mmol/L EDTA (buffer A; pH 6.5). For the platelet suspensions pretreated with dibutyryl cAMP, this buffer also contained 2 mmol/L dibutyryl cAMP. Finally, platelets were resuspended in buffer A without EDTA or dibutyryl cAMP (4.5 mL; pH 7.35). Platelet counts were determined with a CELL-DYN 4000 hematology analyzer (Abbott Diagnostics Division, Abbott Laboratories).
We added nothing to 1-mL aliquots of the platelet suspensions treated with dibutyryl cAMP (nonactivated platelets). To 1-mL aliquots of the platelet suspensions not treated with dibutyryl cAMP, we added CaCl 2 (final concentration, 2. (17, 18 ) . For each sample, 10 000 platelet marker-positive (CD61) events were acquired. To identify marker-positive events, thresholds were set based on samples incubated with similar concentrations of isotype-matched control antibodies.
patient and healthy control groups
Blood samples were obtained from (a) patients with stable angina pectoris (Canadian Society of Cardiology class II) having at least 1 significant (Ͼ50%) coronary stenosis (n ϭ 10); (b) patients with ST-elevation myocardial infarction (STEMI; n ϭ 10) (19 ); (c) patients with non-STEMI (NSTEMI; n ϭ 11) (19 ); and (d) patients with angiographically confirmed peripheral arterial disease (n ϭ 10). We collected blood samples from cardiac patients at the Department of Cardiology of the Academic Medical Center before they underwent catheterization and/or percutaneous coronary intervention. Blood samples from patients with peripheral arterial disease were obtained at the Department of Vascular Surgery before patients underwent elective bypass surgery, and patients were advised to refrain from strenuous exercise at least 24 h before sampling. All NSTEMI patients were sampled within 12 h and all STEMI patients within 6 h after onset of symptoms. All patients received medication according to standard clinical practice. None received coumarin derivatives, thrombolytic therapy, or other antiplatelet medication other than aspirin. Patients with stable angina pectoris received aspirin therapy, whereas those with peripheral arterial disease were advised to refrain from aspirin use for at least 7 days before elective surgery and received prophylactic low-molecular-weight heparin. Patients with MI had received aspirin and low-molecularweight heparin on admission. Blood samples were also obtained from healthy individuals, age-and sex-matched to the patient groups (n ϭ 10), as well as from healthy individuals Ͻ50 years of age (n ϭ 10). The study was approved by the local medical ethics committee of the Academic Medical Center.
Venous blood was collected from the cubital vein into 1/10th volume of 10.9 mmol/L trisodium citrate (BD Diagnostics) with minimal venous occlusion. All blood samples were collected by a single clinician (P.M.v.d.Zee) and processed within 30 min. Blood samples were centrifuged (20 min at 1550g) at room temperature. Only the upper two-thirds of the apparent plasma fraction were collected and briefly mixed in a plastic 10-mL tube. Aliquots of 250 L were immediately snap-frozen in liquid nitrogen for at least 15 min, to be finally stored at Ϫ80°C until assay.
mp isolation and flow cytometric analysis
We isolated MPs as described previously (17, 18 ) . Samples were analyzed in a FACSCalibur with CellQuest software (BD Diagnostics) (18 ) . We doublestained MP samples from 6 patients in each group with annexin V and a cell-specific monoclonal antibody; we triple-stained MPs from 10 patients in each group with annexin V, anti-CD61, and either anti-P-selectin or anti-CD63. MPs were analyzed for 1 min and identified by their characteristic FSC and SSC and by their ability to bind annexin V and a cell-specific monoclonal antibody (17, 18, 20 ) . 
statistical analysis
All data not gaussian distributed are presented as the median (interquartile range); other data are presented as the mean (SD). t-Tests and Mann-Whitney U-tests were used for comparisons of gaussian-and nongaussiandistributed data, respectively. The 2 test was used for comparison of dichotomous variables. For multiple comparisons, the Kruskal-Wallis test or one-way ANOVA for matched samples was used, followed by the Bonferroni multiple comparison test. Correlations were calculated in patients and healthy persons together, with the Spearman rank correlation test. P Ͻ0.05 was regarded as statistically significant.
Results
Washed human platelets (n ϭ 6) were stimulated with either TRAP (15 mol/L) or the calcium ionophore Fig. 1A , compared with nonactivated (i.e., dibutyryl cAMP-treated) platelets, the fractions of platelets exposing P-selectin (CD62p) or CD63 increased strongly in response to both TRAP and A23187 (P Ͻ0.001 for both P-selectin and CD63, using either agonist). Platelet disappearance during stimulation was negligible (P Ͼ0.05 compared with nonactivated platelets; data not shown).
A23187 (2.5 mol/L). As shown in
The fractions of PMPs exposing P-selectin or CD63 in response to TRAP or A23187 are shown in Fig. 1B . Compared with nonactivated platelets, the fractions of PMPs exposing P-selectin or CD63 increased on incubation with TRAP or A23187 (P Ͻ0.001 for both P-selectin and CD63, using either agonist).
Numbers of PMP released in response to stimulation with TRAP were not different when compared with nonactivated platelets (Fig. 1C) . Only stimulation with A23187 increased PMP numbers (P Ͻ0.001).
The baseline characteristics of patients and controls are shown in Table 1 . There were no significant differences in age and sex between the older healthy persons and the other groups [young healthy persons (except for age) and patients with stable angina pectoris, peripheral arterial disease, NSTEMI, or STEMI]. Patients with stable angina had a higher body mass index than the older healthy persons (27.8 vs 23.3 kg/m 2 ; P ϭ 0.012). None of the healthy individuals had clinically manifest cardiovascular disease.
In each group studied, the majority of MPs originated from platelets ( Fig. 2A) . The median overall fraction of CD61-exposing MPs was 96% (interquartile range, 93%-98%), and the numbers did not differ among groups (P ϭ 0.954, Kruskal-Wallis test). The other MPs (Fig. 2B ) originated from erythrocytes (positive for glycophorin A; median, 4%; interquartile range, 1%-7%) and to a lesser extent (Յ2%) from T-helper cells (CD4), T-suppressor cells (CD8), monocytes (CD14), B cells (CD20), endothelial cells (CD62e), and granulocytes (CD66e). Because no differences among groups were observed regarding numbers and cellular origin of the nonplatelet MPs, the data are summarized for all groups in Fig. 2B .
Representative dot-plots of CD61-exposing (P)MPs, as detected in an older healthy person (panel A) and an NSTEMI patient (panel B) are shown in Fig. 3 . Staining with anti-P-selectin revealed that the NSTEMI patient had a relatively large subpopulation of PMPs that exposed P-selectin (Fig. 3D , upper right quadrant) compared with the healthy control (Fig. 3C) . As is also evident in Fig. 3 , all P-selectin-exposing MPs were PMPs, i.e., the upper left quadrants of panels C and D do not show any events.
The fractions of PMPs that exposed P-selectin (panel A) or CD63 (panel B) are shown in Fig. 4 . Comparison among groups (Kruskal-Wallis test) showed significant differences for both P-selectin and CD63 (P Ͻ0.001 and P ϭ 0.007, respectively). Compared with the young healthy group, the P-selectin-exposing subpopulations were increased in older individuals (P ϭ 0.028) and were further increased in NSTEMI (P ϭ 0.007) and STEMI (P ϭ 0.045) patients. CD63-exposing subpopulations were increased in patients with peripheral arterial disease (P ϭ 0.041), NSTEMI (P ϭ 0.001), and STEMI (P ϭ 0.049). Previous use of aspirin in NSTEMI (6 of 11 patients) and STEMI patients (4 of 10 patients) did not affect the exposure of P-selectin or CD63 (data not shown). The numbers of PMPs exposing P-selectin or CD63 correlated strongly (r ϭ 0.581; P Ͻ0.001).
The concentrations of TAT and F 1 ϩ 2 are shown in Table 2 . There were no significant differences in TAT and F 1 ϩ 2 concentrations among groups (Kruskal-Wallis test), and there were no correlations between subpopulations of PMPs exposing P-selectin or CD63 and concentrations of TAT [r ϭ 0.086 (P ϭ 0.512) and r ϭ 0.055 (P ϭ 0.677), respectively] or F 1 ϩ 2 [r ϭ Ϫ0.131 (P ϭ 0.314) and r ϭ Ϫ0.166 (P ϭ 0.209), respectively].
MP-associated P-selectin constituted only 2.2 (4.7)% [mean (SD)] of total concentrations of sP-selectin in plasma, as assessed from the difference between concentrations of P-selectin in MP-containing plasma and in MP-depleted plasma after high-speed centrifugation (30 min at 17 570g and 20°C). We found no correlations between the P-selectin-exposing subpopulation of PMPs and either the total concentrations of sP-selectin (r ϭ 0.153; P ϭ 0.240) or the calculated MP-associated fraction of sP-selectin (r ϭ Ϫ0.003; P ϭ 0.991). 
Discussion
The present study shows that PMP subpopulations exposing P-selectin or CD63 reflect platelet activation in vitro more closely than overall numbers of PMPs. Because platelet activation increases with age and in atherosclerotic disease (21, 22 ) , we studied the presence of PMPs and PMP subpopulations in aging and in atherosclerotic disease in vivo. In our study, the majority of circulating MPs originated from platelets in all individuals. PMP subpopulations, but not the total numbers of PMPs, increased with age and in patients with peripheral arterial disease and in MI. Gawaz et al. (23 ) reported that, in the early stage of MI, the fraction of P-selectin-exposing platelets was increased but not the numbers of PMPs. This early stage was followed after 8 h by an increase in the numbers of PMPs and by a concomitant decrease in platelet counts. These data indicated that the total numbers of PMPs are not an early and sensitive marker of platelet activation in vivo. Rather, the late increase in PMP and decrease in platelet count may be a consequence of altered thrombopoiesis in response to the inflammatory reaction during MI (24 ) .
Thus, discrepancies occur between exposure of P-selectin on platelets and the numbers of PMPs, which we have found in vitro and others in vivo (6, 7, (12) (13) (14) . These discrepancies may be attributed, at least in part, to the persistent release of MPs by megakaryocytes. Such MPs may be erroneously identified as PMPs because of similar antigenic profiles (25 ) .
Our results thus indicate that PMP subpopulations may constitute a novel (plasma) marker for in vivo platelet activation. This marker not only reflects platelet activation better than the total numbers of circulating PMPs, but is also more feasible than measurement of the exposure of P-selectin on platelets. As the major fraction of sP-selectin in plasma is not associated with MPs, direct determination of the MP-associated fraction of sP-selectin by ELISA is impossible. We are currently developing an ELISA capture assay for both CD61 and P-selectin.
Determination of PMP subpopulations may also be used in monitoring the risk-reducing effects of antiplatelet drugs. With regard to the present study, we found ongoing platelet activation despite previous use of aspirin. This is in line with reports of increased platelet activation after coronary stent implantation under aspirin use (26 ) . Thus, the risk-reducing properties of aspirin may be related, at least in part, to mechanisms other than attenuation of platelet activation.
In conclusion, our in vitro data show that PMP subpopulations reflect the platelet activation status. Increased concentrations of circulating PMP subpopulations are found in aging, and further increases are encountered in peripheral arterial disease and MI.
